第 589 回生医研セミナー(多階層生体防御システム研究拠点)
グローバルCOE理医連携セミナー
ゲノミクスエピゲノミクス研究拠点セミナー

この度、愛知県がんセンター研究所分子腫瘍学部の近藤豊先生に生体防御医学研究所でのセミナーをお願い致しました。
このセミナーでは、グリオーマ幹細胞を用いて得られた腫瘍細胞の可塑性と、それに関与するエピゲノムやマイクロRNAの変化についてお話しいただきます。講演は英語で行われます。ご来聴を歓迎致します。

演題Epigenetic switch regulates the plasticity of cancer stem cell in glioblastoma (seminar in English)

演者近藤 豊 先生
愛知県がんセンター研究所分子腫瘍学部 室長
Dr. Yutaka Kondo
Division of Molecular Oncology, Aichi Cancer Center Research Institute

日時平成23年10月21日(金)16時より17時まで
Oct. 21, 2011(Fri), 16:00-17:00

場所馬出医学系キャンパス内 生体防御医学研究所 本館1階 会議室
以下の地図の21番になります。
http://www.kyushu-u.ac.jp/access/map/hospital/hospital.html

Medical Institute of Bioregulation, Main Building 1F, Seminar Room
No.21 on the following linked map
http://www.kyushu-u.ac.jp/access/map/hospital/hospital-e.html

要旨 Tumor cell plasticity contributes to functional and morphological heterogeneity. To uncover the mechanisms underlying this plasticity, we examined glioma stem cell (GSC). We found that biological interconversion between GSCs and differentiated non-GSCs is functionally plastic and accompanied by gain or loss of polycomb repressive complex 2 (PRC2)-mediated histone H3 lysine 27 trimethylation on pluripotency or development associated genes (e.g. Nanog, Wnt1, BMP5) and small RNA (miR-1275) together with alterations in the subcellular localization of EZH2, a catalytic component of PRC2. The subcellular localization of EZH2 has been shown to be associated with tumor cell differentiation in glioblastoma specimens. Inhibition of EZH2 disrupted the morphological interconversion and impaired GSC integration into the brain tissue, resulting in improved survival of GSC-bearing mice. Our data suggest that epigenetic regulation by PRC2 is a key mediator of tumor cell plasticity and tumor heterogeneity, and that targeting this plasticity may provide a new strategy in glioblastoma treatment.
  1. Okamoto Y. et al. Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut. (in press).
  2. Goto Y. et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 69: 9073-82, 2009.
  3. Kondo Y. et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 40: 741-50, 2008.

連絡先生体防御医学研究所 エピゲノム学分野 佐々木 裕之
Division of Epigenomics, MIB, Hiroyuki SASAKI
電話:092-642-6759


Copyright 2003 Medical Institute of Bioregulation Kyushu University. All Rights Reserved.